EIRION's GNN Jumps Tox21 AUC from 0.75 to Context-Aware Heights
Drug models stalled at 0.7517 AUC because they treated molecules like solo acts. EIRION's graph neural network stages the full biological drama, promising fewer trial flops.
⚡ Key Takeaways
- Random Forest baselines hit 0.7517 AUC on Tox21 but miss biological context like gene-pathway interactions.
- EIRION's GATv2 graph neural net models compounds, genes, and pathways together for sharper toxicity predictions.
- Potential to slash pharma's $50B annual trial failures—game-on for AI in drug discovery.
🧠 What's your take on this?
Cast your vote and see what theAIcatchup readers think
Worth sharing?
Get the best AI stories of the week in your inbox — no noise, no spam.
Originally reported by Towards AI